[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-airways-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-airways-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100616952","small-airways-disease-functional-assessment-in-idiopathic-pulmonary-fibrosis-swift-ipf-100616952",false,"NCT07312305","Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis (SWIFT-IPF)","SWIFT-IPF","Inclusion Criteria:\n\n* Age over 18 years\n* IPF of any degree of severity, diagnosed according to the 2022 ATS\u002FERS\u002FJRS\u002FALAT guidelines\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patients unable to provide informed consent for participation in the study\n* IPF exacerbation in the 6 months prior to enrollment\n* Previous diagnosis of chronic airway disease (e.g., bronchial asthma, chronic obstructive bronchitis, bronchiectasis with a cause other than IPF)\n* Presence of bronchial obstruction defined by an FEV1\u002FFVC (or FEV1\u002FVC) ratio below the lower limit of normal\n* Chronic therapy with long-acting bronchodilators or combinations of bronchodilators and inhaled corticosteroids\n* Inability of the patient to perform reproducible pulmonary function tests\n* Chronic treatment with systemic corticosteroids or immunosuppressants\n* Concomitant lung or pleural cancer\n* Pregnancy or breastfeeding women","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing, and progressive lung disease of unknown cause, whose incidence increases proportionally from the age of 60. It is characterized by a poor prognosis. Antifibrotic therapy can slow the progression of the disease and reduce mortality, but the life expectancy is less than 7-10 years in the vast majority of patients with IPF. There are no studies in the literature that have evaluated the presence of small airway disease in patients with IPF prior to the initiation of pharmacological therapy, using the nitrogen washout test. This test is currently considered the only non-invasive method capable of detecting ventilation inhomogeneity and closing volume, which are indicators of small airway dysfunction. The investigators carried out an Italian prospective, observational, multicenter study with the primary aim to assess the prevalence of small airway disease measured by the nitrogen washout test (evaluating the following functional parameters: phase 3 slope, closing volume, closing capacity, closing volume\u002Fvital capacity, closing capacity\u002Ftotal lung capacity, and phase 4 slope) in a group of patients with IPF at the time of diagnosis, before the initiation of antifibrotic therapy. During outpatients visits clinical, functional and radiological data will be collected. Results will be compared to an healthy control group matched with IPF population. Variations in small airways disease parameters will be assessed after one year of antifibrotic treatment.",[24,25],"Idiopathic Pulmonary Fibrosis","Small Airways Disease",[27,28,29],"IPF","SAD","SBW-N₂","RECRUITING","2026-01-26",{"date":33,"type":34},"2026-01-28","ACTUAL",{"date":36,"type":34},"2025-05-15",{"date":38,"type":20},"2027-05-15",{"name":40,"class":41},"University of Milan","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100620943","bronchodilator-response-in-copd-and-asthma-correlation-between-spirometry-ios-indices-and-dyspnea-relief-100620943","NCT07364188","Bronchodilator Response in COPD and Asthma: Correlation Between Spirometry, IOS Indices, and Dyspnea Relief","Inclusion Criteria:\n\n* Both asthma and COPD patients:\n\n  1. Written informed consent.\n  2. FEV1\u002FForced Vital Capacity (FVC) \\\u003C0.7 at baseline (7)\n  3. Visual Analog Scale (VAS) dyspnea score ≥10 (0-100, 100 max) (25,26).\n* Asthma: Doctor diagnosed asthma\n\n  1\\. less than 10 packyears.\n* COPD: Doctor diagnosed COPD with FEV1\u002FFVC \\\u003C0.7 post-bronchodilation 1. Smokers or ex-smokers with ≥10 packyears\n\nExclusion Criteria:\n\n* Patients aged less than 18 years old.\n* Not able to perform spirometry or impulse oscillometry.\n* Cognitive disorders and not able to answer Asthma Control Questionnaire (ACQ), VAS dyspnea score, and COPD Assessment Test (CAT) score (25-28).\n* Short-acting beta-agonists 6 h, long-acting beta-agonists 2 days, short-acting anti-muscarinic agent 12 h, Long-acting anti-muscarinic agents 2 days.\n* Comorbidities with significant influence on dyspnea eg. bronchiectasis, ILS, mb. Cordis, lung resection, anemia, and active malignant disease\n* BMI ≥40 kg\u002Fm2.",{"count":49,"type":20},120,"A bronchodilator reversibility test is widely used in the diagnosis and management of obstructive lung diseases.\n\nBronchodilators relieve symptoms in asthma and COPD. Traditionally, their effectiveness has been assessed using spirometric indices, particularly FEV₁. However, changes in FEV₁ often do not correlate well with patients' subjective experience of dyspnoea relief or with changes in small airway function.\n\nImpulse oscillometry (IOS) provides an effort-independent assessment of respiratory mechanics during tidal breathing and is more sensitive to small airway dysfunction than spirometry. Despite this, the clinical utility of IOS in routine COPD and asthma assessment remains underexplored, and its relationship to both spirometric response and symptom relief is not fully established, and the Minimal Clinically Important Difference (MCID) for IOS parameters has not been firmly established. Determining the MCID is essential for interpreting individual patient responses in a clinically meaningful way and for guiding treatment decisions in both research and practice.\n\nHypothesis \\& Aims\n\nIn patients with either asthma or COPD baseline values and bronchodilator responses are compared. More specifically, this study aims to:\n\n1. assess baseline correlations: Evaluate the correlation between ΔX5-baseline (EFL expiratory flow limitation=small airway collapse during expiration), RV\u002FTLC-baseline, X5-average at baseline, FEV1-baseline, VAS-dyspnea at baseline, and ACQ-6-baseline.\n2. compare bronchodilator responses across methods: Examine the correlation between bronchodilator-induced changes in FEV₁ and IOS parameters (including both average and delta values) and explore their relationship with short-term changes in dyspnea.\n3. establish clinical relevance: Determine the MCID for key IOS variables using both anchor-based and distribution-based approaches, anchored to perceived changes in lung symptoms.",[52,53,54,55,56,25],"Asthma Bronchiale","COPD","Bronchodilation","Spirometry","Impedance",[58,53,59,60,61],"asthma","Correlation","Bronchodilator response","MCID","NOT_YET_RECRUITING","2026-01-23",{"date":31,"type":34},{"date":66,"type":20},"2026-02-01",{"date":68,"type":20},"2027-12-31",{"name":70,"class":71},"Allergi- og Lungeklinikken, Elsinore","NETWORK"]